| Date | Title | Description |
| 01.09.2026 | Immunophotonics Secures Initial $10 Million Series C Financing and Appoints Robert H. Arch, Ph.D., as President and CEO | Financing & CEO Transition Support Advancement of IP-001 Clinical Development and Strategic Growth Initiatives SAINT LOUIS, MO, UNITED STATES, September 1, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech compa... |
| 16.06.2026 | Immunophotonics Secures Key Patent in China, Expanding Global Intellectual Property Portfolio | This patent reinforces strategic protection of core platform technology across key global markets SAINT LOUIS, MO, UNITED STATES, June 16, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on develop... |
| 19.05.2026 | Data from Immunophotonics Phase 1b/2a Clinical Trial to Be Presented at ASCO 2026 | By activating systemic adaptive immunity, IP 001 may enable immune effector cells to identify and eliminate tumor cells throughout the body. SAINT LOUIS, MO, UNITED STATES, May 19, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinica... |
| 24.02.2026 | Immunophotonics Secures European Patent Protecting Use of Lead Asset in Combination with Checkpoint Inhibitors | Additional intellectual property protection reinforces the strategic value of IP-001 and supports ongoing clinical development efforts. SAINT LOUIS, MO, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinica... |
| 15.04.2025 | Jacqueline Hess Joins Immunophotonics Board of Directors | ST. LOUIS, MO, UNITED STATES, April 15, 2025 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on immuno-oncology, is pleased to announce the appointment of Jacqueline Hess to its Board of Directors. With... |
| 13.09.2024 | Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3 | ST. LOUIS, MO, UNITED STATES, September 13, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biopharma company developing novel immune-stimulating drugs to augment routine tumor destruction techniques – such as tumor ablat... |
| 15.08.2024 | Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville | SAINT LOUIS, MISSOURI, USA, August 15, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, in collaboration with Dr. Robert CG Martin ... |
| 26.06.2024 | Envisioning a future where food is synonymous with health, fostering longevity, productivity, and societal well-being | If you missed Carter’s testimony at the Senate hearing, “Feeding a Healthier America: Current Efforts and Potential Opportunities for Food is Medicine,” the replay is available here.
The hearing emphasized the importance of nutrition to red... |
| 27.02.2024 | AngioDynamics and Immunophotonics Announces Partnership to Explore the Power of Immunotherapy | LATHAM, NEW YORK, February 27, 2024 /EINPresswire.com/ -- AngioDynamics, Inc. (NASDAQ: ANGO), a global provider of medical devices, and Immunophotonics, Inc., a clinical-stage biopharma company focused on immuno-oncology, are pleased to ann... |
| 12.07.2023 | Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in Germany | ST. LOUIS, MISSOURI, July 12, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment and the dosing of its f... |
| 31.05.2023 | Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in the United Kingdom | SAINT LOUIS, MISSOURI, AND BERN SWITZERLAND, May 31, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment ... |
| 16.05.2023 | Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S. | ST. LOUIS, MISSOURI, USA, May 16, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel innate immune stimulating drugs with antigen depot properties, has announc... |
| 24.01.2023 | Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications | SAINT LOUIS, MISSOURI, USA, January 24, 2023 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the initiation of recruitmen... |
| 25.10.2022 | Immunophotonics Co-Founder Wei Chen, Ph.D. Awarded $2.5 Million Grant by the National Cancer Institute | SAINT LOUIS, MISSOURI, USA, October 25, 2022 /EINPresswire.com/ -- Immunophotonics, Inc. announced today that Wei Chen, Ph.D., co-founder and director of Immunophotonics, Inc. and Professor and Stephenson Chair of Biomedical Engineering, in... |
| 10.05.2022 | Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications | ST. LOUIS, MISSOURI AND BERN, SWITZERLAND, May 10, 2022 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disea... |
| 13.04.2022 | Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors | ST. LOUIS, MISSOURI, USA, April 13, 2022 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious disease, has strengt... |
| 06.04.2022 | Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials | ST. LOUIS, MISSOURI, AND BERN, SWITZERLAND, April 6, 2022 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs in oncology and infectious dis... |
| 13.01.2021 | Techshare reveals its 2021 cohort with 13 Swiss startups | |
| 13.01.2021 | Techshare reveals its 2021 cohort with 13 Swiss startups | The sixth edition of TechShare by Euronext, the pan-European stock exchange, welcomes 119 Tech companies from ten countries to participate in the first half of 2021. This number is expected to grow as participants join the IPOready programm... |
| 15.07.2019 | 2 Companies That Are Working to Cure Cancer Right Now | In 2018, an estimated 1,735,350 new cases of cancer were diagnosed in the United States and 609,640 people died as a result of the disease, according to the National Cancer Institute. These numbers are staggering.
The challenge for clinicia... |
| 19.06.2018 | Un premier IPO Day lausannois couronné de succès | |
| 04.04.2017 | Immunophotonics, SAKK Move Forward with Research Collaboration | Cancer care is entering a new age, transitioning from treatments that attack both cancerous and healthy cells at the same time, to more targeted, specialized therapies that address the root cause of cancer itself without damaging surroundin... |
| 20.01.2015 | BioTech Selection Committee: Bobby Sandage | Spotlight: Selection Committee Member
A Brief Background:
Bobby W. Sandage, Jr., Ph.D. has 34 years of experience in the pharmaceutical and biotech industry and was recently appointed President and CEO of Euclises Pharmaceuticals a St. Loui... |
| 11.07.2011 | Cancer vaccine firm Immunophotonics wants clinical trials within six months | Immunophotonics co-founder and CEO Tomas Hode said that the drug has shown long-term immunity against cancer in tests on animals. The drug could also cost less than other vaccines under development, Hode said.
“It’s a personal vaccine where... |
| - | ImmunoPhotonics | “Immunophotonics' proprietary glycan polymer enhances antigen capture & immune processes, unlocking platform potential for immunotherapy.” |
| - | ImmunoPhotonics | “UNLOCKING THE POTENTIAL OF THE IMMUNE SYSTEM WITH A NEW CLASS OF THERAPEUTICS Immunophotonics uses a proprietary glycan polymer with platform potential to stimulate antigen capture and uptake along with other immunological processes that a... |
| - | Cancer vaccine firm Immunophotonics wants clinical trials within six months | A Missouri biotech company developing a laser-guided cancer vaccine therapy is raising money to get into clinical trials by the end of the year.
Immunophotonics has so far focused its laser-assisted immunotherapy, called inCVAX, primarily o... |
